Antibody-Drug Conjugates and Immunotoxins

From Pre-Clinical Development to Therapeutic Applications

  • Gail Lewis Phillips

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Introduction and Development Perspectives

    1. Front Matter
      Pages 1-1
    2. Aakanksha Khandelwal, Haleh Saber, Marjorie A. Shapiro, Hong Zhao
      Pages 23-38
  3. Development of Antibody-Drug Conjugates

    1. Front Matter
      Pages 39-39
    2. Katherine R. Kozak, Helga Raab
      Pages 41-56
    3. David Dornan, Jeff Settleman
      Pages 77-90
  4. Selection of Cytotoxic Agents

    1. Front Matter
      Pages 91-91
    2. Victor S. Goldmacher, Rajeeva Singh, Thomas Chittenden, Yelena Kovtun
      Pages 117-135
  5. Antibody-Drug Conjugates for Hematologic Malignancies

    1. Front Matter
      Pages 137-137
    2. John M. Lambert, Veronique Blanc, Nathalie Le Bail, Anne Bousseau
      Pages 149-160
    3. Andres Forero, Christos Vaklavas, Albert F. LoBuglio
      Pages 161-175
  6. Antibody-Drug Conjugates for Solid Tumors

    1. Front Matter
      Pages 177-177
    2. Christos Vaklavas, Albert F. LoBuglio, Mansoor Saleh, Michael Yelin, Andres Forero
      Pages 211-220
    3. Douglas Leipold, William G. Mallet
      Pages 221-239
    4. Zhan Xiao, Dowdy Jackson, David A. Tice
      Pages 241-253

About this book

Introduction

The concept of delivering ‘magic bullets’ to treat diseases was first proposed by Paul Erlich in the early 1900’s.  The realization of this concept for the treatment of cancer occurred in the late 1990’s with the approval of monoclonal antibody therapies.  The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. 

ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics.  More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use.  This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.

Keywords

antibodies conjugates immunotoxins therapeutics

Editors and affiliations

  • Gail Lewis Phillips
    • 1
  1. 1.South San FranciscoUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4614-5456-4
  • Copyright Information Humana Press 2013
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine
  • Print ISBN 978-1-4614-5455-7
  • Online ISBN 978-1-4614-5456-4
  • About this book